Related Experiment Video

Updated: Aug 6, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

New approaches for the management of patients with multiple cardiometabolic risk factors

L F Van Gaal1, F Peiffer

  • 1Department of Diabetology, Metabolism and Clinical Nutrition, Antwerp University Hospital, Antwerp, Belgium. luc.van.gaal@uza.be

Journal of Endocrinological Investigation
|June 6, 2006
PubMed

Insights

Rimonabant, a cannabinoid receptor type 1 (CB1) blocker, effectively reduced weight and improved cardiometabolic risk factors like HDL-C, triglycerides, and insulin resistance in overweight/obesity patients. These benefits, including reduced waist circumference, were observed to be beyond weight loss alone.

Area of Science:

  • Cardiology
  • Metabolic Syndrome
  • Pharmacology

Background:

  • Current cardiometabolic risk management targets individual factors, not underlying disease causes.
  • Overweight and obesity are significant risk factors for cardiovascular and metabolic diseases.

Purpose of the Study:

  • To assess the efficacy and safety of rimonabant in treating multiple cardiometabolic risk factors.
  • To evaluate rimonabant's impact on weight, waist circumference, lipid profiles, and glucose metabolism in overweight/obesity patients.

Main Methods:

  • The Rimonabant-in-Obesity (RIO) program included four Phase III trials (RIO-Europe, RIO-Lipids, RIO-North America, RIO-Diabetes).
  • Over 6600 overweight/obesity patients received rimonabant 20mg/day or placebo for 1-2 years.

Main Results:

  • Rimonabant significantly improved HDL-C, triglycerides, fasting insulin, and insulin resistance compared to placebo (p<0.001).
  • Sustained reductions in waist circumference and weight were observed with rimonabant (p<0.001).
  • Improvements in HDL-C, triglycerides, and insulin resistance were greater than could be attributed to weight loss alone.

Conclusions:

  • Rimonabant, the first CB1 receptor blocker, demonstrates significant efficacy in reducing cardiometabolic risk factors.
  • The drug is well-tolerated, with mild and transient adverse events, offering a novel therapeutic approach.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...